Tvardi Therapeutics, Inc. (TVRD)
0.8571
-0.01
(-0.86%)
USD |
NASDAQ |
Nov 06, 10:41
Tvardi Therapeutics EPS Diluted (Quarterly) : -0.6883 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.6883 |
| March 31, 2026 | -0.7253 |
| December 31, 2025 | -0.7755 |
| September 30, 2025 | -0.5894 |
| June 30, 2025 | -1.004 |
| March 31, 2025 | -3.719 |
| December 31, 2024 | -4.936 |
| September 30, 2024 | -77.08 |
| June 30, 2024 | -32.51 |
| March 31, 2024 | -20.24 |
| December 31, 2023 | -21.37 |
| September 30, 2023 | -18.61 |
| June 30, 2023 | -20.98 |
| March 31, 2023 | -17.82 |
| December 31, 2022 | -20.32 |
| September 30, 2022 | -15.53 |
| June 30, 2022 | -2.824 |
| March 31, 2022 | -18.67 |
| December 31, 2021 | -22.78 |
| September 30, 2021 | -0.7276 |
| June 30, 2021 | -22.11 |
| March 31, 2021 | -16.80 |
| December 31, 2020 | 57.16 |
| September 30, 2020 | -12.68 |
| June 30, 2020 | -19.28 |
| Date | Value |
|---|---|
| March 31, 2020 | -22.28 |
| December 31, 2019 | -22.06 |
| September 30, 2019 | -26.56 |
| June 30, 2019 | -20.76 |
| March 31, 2019 | -19.99 |
| December 31, 2018 | -18.85 |
| September 30, 2018 | -18.36 |
| June 30, 2018 | -18.72 |
| March 31, 2018 | -18.47 |
| December 31, 2017 | -15.48 |
| September 30, 2017 | -13.68 |
| June 30, 2017 | -10.44 |
| March 31, 2017 | -29.16 |
| December 31, 2016 | -29.16 |
| September 30, 2016 | -15.12 |
| June 30, 2016 | -17.28 |
| March 31, 2016 | -14.04 |
| December 31, 2015 | -12.59 |
| September 30, 2015 | -6.84 |
| June 30, 2015 | -9.00 |
| March 31, 2015 | -7.56 |
| December 31, 2014 | -6.48 |
| September 30, 2014 | -10.44 |
| June 30, 2014 | -5.76 |
| March 31, 2014 | -7.92 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 1.052 |
| Corcept Therapeutics, Inc. | 1.010 |
| Veru, Inc. | -0.3032 |
| Johnson & Johnson | 0.0858 |
| Eli Lilly & Co. | 7.221 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -6.457M |
| Total Expenses (Quarterly) | 6.457M |
| Enterprise Value | -7.510M |
| Earnings Yield | -324.2% |
| Normalized Earnings Yield | -324.17 |